Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00869089 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of CC-10004 for Prurigo Nodularis
A Phase 2 study of Prurigo Nodularis, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT00869089 is a Phase 2 study of Prurigo Nodularis that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 5 participants, below the 229-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00869089, a Phase 2 study of Prurigo Nodularis, has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will include: * Study period up to 7 months. * Office visits monthly lasting approximately 1 hour. * Blood Draws. * Oral medication that is taken 2 times daily. * Photographs and biopsies if agreed.
Conditions Studied
Interventions
- DRUG CC-10004
Study Locations (1)
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00869089
The ClinicalTrials.gov registry entry for NCT00869089 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 229-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (98% lower). The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 1 intervention - of which CC-10004 is the first listed.
NCT00869089 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00869089 about?
NCT00869089 is a clinical study titled "Safety and Efficacy of CC-10004 for Prurigo Nodularis". This trial will include: * Study period up to 7 months. * Office visits monthly lasting approximately 1 hour. * Blood Draws. * Oral medication that is taken 2 times daily. * Photographs and biopsies if agreed.
What is the current status of trial NCT00869089?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2008-09. Estimated completion is 2011-01.
What conditions does trial NCT00869089 study?
This clinical trial studies the following conditions: Prurigo Nodularis.
What interventions are being tested in trial NCT00869089?
The interventions under investigation include: CC-10004 (DRUG).
Who is sponsoring clinical trial NCT00869089?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00869089 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Barzolvolimab in Patients With Prurigo Nodularis
ACTIVE NOT RECRUITING · Phase 2
-
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
RECRUITING · Phase 3
-
Upadacitinib for Prurigo Nodularis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.